Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | CASP7 | P55210 | 3/20 | 0.49 |
| ▸ | BAP1 | Q92560 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | FFAR3 | O14843 | 9/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7981102 | 0.86 | HSD17B10 (0.64) | HSD17B10ALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL8803951 | 0.85 | HSD17B10 (0.46) | HSD17B10ALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL3323212 | 0.84 | ALDH1A1 (0.66) | HSD17B10ALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL3324905 | 0.84 | ALDH1A1 (0.71) | HSD17B10ALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL5197527 | 0.84 | FFAR3 (0.60) | HSD17B10ALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL3324018 | 0.83 | SMN1; SMN2 (0.58) | HSD17B10ALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL5223944 | 0.81 | ALDH1A1 (0.69) | HSD17B10ALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL5227040 | 0.81 | KDM4E (0.47) | HSD17B10ALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL9048171 | 0.79 | HSD17B10 (0.49) | HSD17B10ALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL2563899 | 0.79 | TSHR (0.62) | HSD17B10ALDH1A1HPGDCASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814554-A1 | CERTAIN COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060116369-A1 | Certain compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-06-01 | — | — | US | claimed |
| WO-2006047537-A1 | CERTAIN COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2006-05-04 | — | — | WO | claimed |
| EP-1814554-A1 | CERTAIN COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060116369-A1 | Certain compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2006047537-A1 | CERTAIN COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116369-A1 | Certain compounds, compositions, and methods | PCNA, MKI67, TP53 | HSD17B10 967/4885ALDH1A1 791/4885HPGD 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.